Status:

COMPLETED

Late Night Study 2: End-of-Day Assessment of Asymptomatic and Symptomatic Soft Lens Wearers

Lead Sponsor:

Johnson & Johnson Vision Care, Inc.

Conditions:

Visual Acuity

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

This is a 2-Part, 8-Visit, single-center, open-label, bilateral and dispensing clinical study. In Part 1 (Visits 1-4) all subjects will be Test Lens 1, in Part 2 (Visits 1-4) eligible subjects will be...

Eligibility Criteria

Inclusion

  • Potential subjects must satisfy all of the criteria listed to be enrolled in the study.
  • They are 18-45 years of age (inclusive).
  • They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
  • They are willing and able to follow the protocol.
  • They agree not to participate in other clinical research while enrolled on this study.
  • They currently use daily disposable soft daily wear contact lenses (worn bilaterally) (within the last six months) which may be spherical, toric or multifocal.
  • They agree to wear their lenses for at least 12-14 hours per day.
  • They own a wearable pair of spectacles (by self-report).
  • They have a spherical contact lens prescription in the range +6.00 to -10.00 DS (based on the calculated ocular refraction).
  • They have up to a maximum of 1.00 DC of refractive astigmatism (based on the calculated ocular refraction).
  • They have best corrected distance visual acuity of at least 0.20 binocularly

Exclusion

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • They have an ocular disorder which would normally contraindicate contact lens wear.
  • They have a systemic disorder which would normally contraindicate contact lens wear.
  • No ocular topical medications (including comfort drops) from 24 hours prior to study visits or during the wear of any study lenses.
  • They are regularly using anti-inflammatory or pain medications (i.e. medication routinely used more than twice per week).
  • They have had cataract surgery.
  • They have had corneal refractive surgery.
  • They are pregnant or breast-feeding.
  • They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. HIV) or a history of anaphylaxis or severe allergic reactions.
  • They are an employee or immediate family member of an employee of the clinical site (e.g. Investigator, Coordinator, Technician).
  • They have taken part in any other clinical trial or research within two weeks prior to starting this study.
  • History of allergy to sodium fluorescein or lissamine green.
  • They have any corneal distortion e.g. as a result of previous rigid lens wear or have keratoconus.
  • They any slit lamp findings of Efron Grade 3 or greater (e.g. corneal edema, corneal neovascularization, tarsal abnormalities, conjunctival injection) or findings of \< Grade 3 which in the investigator's opinion would contraindicate contact lens wear.

Key Trial Info

Start Date :

April 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 3 2022

Estimated Enrollment :

196 Patients enrolled

Trial Details

Trial ID

NCT03871543

Start Date

April 1 2019

End Date

February 3 2022

Last Update

May 16 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Manchester - Eurolens Research

Manchester, United Kingdom